The clear star of this year's American Society of Clinical Oncology (ASCO) meeting in Chicago was the antibody approach to Programmed Death (PD-1) for solid tumors. Responses are greater than 50% and likely to be sustained.
The initial target indications are melanoma and non-small cell lung cancer (NSCLC), due to the rich antigen environment for both.
It's now a horse race between BMS and Merck to be the first to the market. Roche is playing catch-up with their antibody to the PD-1 ligand.
Finally, Immunotherapy for Cancer Comes to Life
Related articles
- Combination Immunotherapy For Advanced Melanoma- Phase 1b Trial Results Encouraging
- Investigational Anti-PD-1 Immunotherapy BMS-936558 Clinical Activity In Phase 1 Trial For Non-Small-Cell Lung Cancer
- Immune Therapy For Advanced Bladder Cancer Yields Promising Results
- Investment In Oncology Drug Development Remains Strong As 133 Companies Initiate Late-Stage Clinical Trials Representing A 21% Increase
- KRAS Diagnostic Test That Assists With Personalized Treatment Of Colorectal Cancer Receives CE Mark
Comments